D
The startup develops a digital therapeutic technology that utilizes light stimulation to target specific photosensitive cells in the retina, modulating dopamine levels to regulate eye growth. This clinically validated therapy aims to slow the progression of myopia in children and adolescents.
Updated 18 months ago
Funding
$15.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a digital therapeutic technology that utilizes light stimulation to target specific photosensitive cells in the retina, modulating dopamine levels to regulate eye growth. This clinically validated therapy aims to slow the progression of myopia in children and adolescents.